72 results about "Kinin" patented technology

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.

The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The invention relates to a KIF18 inhibitor with a structure as shown in a formula (I) and a synthesis method thereof, and the compound can regulate KIF18A protein so as to influence a cell cycle and a cell proliferation process to treat cancers and cancer-related diseases. And pharmaceutical compositions comprising the compounds, methods for treating conditions associated with KIF18A activity.

Methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection are provided. Compositions can comprise one or more active agents of small molecules antagonists of arthropod kinin receptor. Methods of preventing disease development and infestation by arthropods are disclosed as well as methods of making, using, and producing such compositions.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The present invention relates to human tissue kallikrein 7 (KLK7) selective inhibitor compounds, combinations including these compounds, process to obtain the referred compounds, and methods of using the same. The present invention belongs to the field of chemistry, pharmacology and medicine.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention discloses a label-free screening method and application of an FPR1 bias agonist screened by the label-free screening method to acute lung injury. According to the invention, Epic label-free screening is combined with calcium flow screening, such that a preliminarily screened FPR1 agonist is obtained; the FPR1 biased agonist is obtained through a G protein dissociation experiment and a beta-arrest collection experiment; the FRP1 antagonist is obtained through screening of a known FPR1 agonist. The FPR1 bias agonist kinetin nucleoside is obtained for the first time, and by detecting the superoxide inhibiting, cast-off cell inhibiting and MPO inhibiting functions of the bias agonist KR, it is proved that the bias agonist KR has the function of treating acute lung injury. The invention discovers that the kinetin nucleoside has the effect of treating the acute lung injury for the first time.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The invention relates to a KIF18 inhibitor and a synthesis method thereof, and the KIF18 inhibitor can regulate KIF18A protein so as to influence the cell cycle and the cell proliferation process to treat cancers and cancer-related diseases. Also included are pharmaceutical compositions comprising the KIF18 inhibitor compounds and methods for treating conditions associated with KIF18A activity.

The present disclosure provides antibodies and polypeptides that specifically bind to kallikrein related peptidase 6 (KLK6). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Aspects of this application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies), as well as methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.

Provided is a non-human animal that is useful for analysis of a kallikrein-kinin system. A non-human animal that lacks the Kng1 gene and the Kng2 gene.

Topical aprepitant formulations and methods of treating epidermal growth factor receptor inhibitor-associated skin toxicities. In some embodiments, the present disclosure pertains to a topical composition comprising a neurokinin-1 receptor antagonist selected from aprepitant or a pharmaceutically acceptable salt thereof or fosaprepitant or a pharmaceutically acceptable salt thereof, and at least one excipient, wherein the composition is a non-aqueous emulsion.

The present invention provides compounds useful for the treatment or prevention of diseases or conditions involving (a) thromboembolic disorders, (b) inflammatory disorders, or (c) plasma kallikrein activity. [Solution] A compound of formula (I), or its tautomers, stereoisomers, isotope substitutions, or pharmaceutically acceptable salts or solvates is provided. TIFF2026062690000101.tif47128

An improved method of administering a neurokinin-1 receptor antagonist, preferably defortupitant, by intravenous injection, preferably for a shortened period of time.

Compositions and methods are provided for editing, e.g., introducing double-strand breaks, within the KLKB1 gene.Compositions and methods are provided for treating a subject with hereditary angioedema (HAE).

Aspects of the application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5xKLK7 antibodies (e.g., bispecific antibodies) and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.